Mesothelioma Treatment

An interesting study is called, Ultrastructural comparison of an adenomatoid tumor, lymphangioma, hemangioma, and Mesothelioma by Joseph B. Marcus MD,, Joseph A. Lynn MD, – Cancer Volume 25, Issue 1, pages 171175, January 1970. Here is an exerpt: Abstract – An electron microscopic study was made comparing an adenomatoid tumor with a hemangioma, lymphangioma, and 2 mesotheliomas in an attempt to elucidate the cell of origin of the adenomatoid tumor. Using ultrastructural criteria, one could say that neither the hemangioma or lymphangioma were structurally related to the adenomatoid tumor. It was not possible to morphologically distinguish between the cells of the mesothelioma and that of the adenomatoid tumor.

Another interesting study is called, Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. By Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. – Cancer Treat Rep. 1985 Jun;69(6):711-2. Here is an excerpt: Abstract – Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

If you have developed mesothelioma as a result of asbestos exposure in the workplace, you may be entitled to financial compensation for your medical expenses, pain, and suffering. There are several aspects to a mesothelioma/asbestos lawsuit that you may want to know a little bit about before contacting a mesothelioma lawyer in your area. While everyone’s case is different, there are a number of steps that will happen for nearly everyone that files an asbestos-related lawsuit with a mesothelioma attorney.

First Steps

Another interesting study is called, Modified RECIST criteria for assessment of response in malignant pleural Mesothelioma by M. J. Byrne and A. K. Nowak – Ann Oncol (2004) 15 (2): 257-260. Here is an excerpt: Abstract – Background: The growth pattern of malignant pleural mesothelioma makes the use of RECIST (response evaluation criteria in solid tumours) response criteria difficult. We have developed and validated Modified RECIST criteria adapted to the growth pattern of malignant pleural mesothelioma. Patients and methods: We evaluated 73 patients from two clinical trials of cisplatin/gemcitabine chemotherapy in malignant pleural mesothelioma. Tumour thickness perpendicular to the chest wall or mediastinum was measured in two positions at three separate levels on thoracic CT scans. The sum of the six measurements defined a pleural unidimensional measure. Bidimensionally measureable lesions were measured unidimensionally as for RECIST. All measurements were added to obtain the total tumour measurement. A reduction of at least 30% on two occasions 4 weeks apart defined a partial response; an increase of 20% over the nadir measurement, progressive disease. The validity of the modified criteria was gauged by evaluating survival and pulmonary function. Results: Response according to these criteria predicted for superior survival (15.1 versus 8.9 months; P = 0.03) and forced vital capacity (FVC) increase during treatment (P